These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 30244079)
1. Bile acid homeostasis paradigm and its connotation with cholestatic liver diseases. Yang T; Khan GJ; Wu Z; Wang X; Zhang L; Jiang Z Drug Discov Today; 2019 Jan; 24(1):112-128. PubMed ID: 30244079 [TBL] [Abstract][Full Text] [Related]
2. New insights into the bile acid-based regulatory mechanisms and therapeutic perspectives in alcohol-related liver disease. Liu Y; Liu T; Zhao X; Gao Y Cell Mol Life Sci; 2022 Aug; 79(9):486. PubMed ID: 35978227 [TBL] [Abstract][Full Text] [Related]
3. New therapeutic concepts in bile acid transport and signaling for management of cholestasis. Trauner M; Fuchs CD; Halilbasic E; Paumgartner G Hepatology; 2017 Apr; 65(4):1393-1404. PubMed ID: 27997980 [TBL] [Abstract][Full Text] [Related]
4. Early indications of ANIT-induced cholestatic liver injury: Alteration of hepatocyte polarization and bile acid homeostasis. Yang T; Mei H; Xu D; Zhou W; Zhu X; Sun L; Huang X; Wang X; Shu T; Liu J; Ding J; Hassan HM; Zhang L; Jiang Z Food Chem Toxicol; 2017 Dec; 110():1-12. PubMed ID: 28986171 [TBL] [Abstract][Full Text] [Related]
5. Bile Acids in Cholestasis and its Treatment. Arab JP; Cabrera D; Arrese M Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s53-s57. PubMed ID: 29080340 [TBL] [Abstract][Full Text] [Related]
6. Sphingosine 1-phosphate receptor-1 specific agonist SEW2871 ameliorates ANIT-induced dysregulation of bile acid homeostasis in mice plasma and liver. Yang T; Wang X; Yuan Z; Miao Y; Wu Z; Chai Y; Yu Q; Wang H; Sun L; Huang X; Zhang L; Jiang Z Toxicol Lett; 2020 Oct; 331():242-253. PubMed ID: 32579994 [TBL] [Abstract][Full Text] [Related]
7. Bile salts and cholestasis. Maillette de Buy Wenniger L; Beuers U Dig Liver Dis; 2010 Jun; 42(6):409-18. PubMed ID: 20434968 [TBL] [Abstract][Full Text] [Related]
8. Predictive Value of Cellular Accumulation of Hydrophobic Bile Acids As a Marker of Cholestatic Drug Potential. Burban A; Sharanek A; Humbert L; Eguether T; Guguen-Guillouzo C; Rainteau D; Guillouzo A Toxicol Sci; 2019 Apr; 168(2):474-485. PubMed ID: 30629237 [TBL] [Abstract][Full Text] [Related]
10. MYO5B and bile salt export pump contribute to cholestatic liver disorder in microvillous inclusion disease. Girard M; Lacaille F; Verkarre V; Mategot R; Feldmann G; Grodet A; Sauvat F; Irtan S; Davit-Spraul A; Jacquemin E; Ruemmele F; Rainteau D; Goulet O; Colomb V; Chardot C; Henrion-Caude A; Debray D Hepatology; 2014 Jul; 60(1):301-10. PubMed ID: 24375397 [TBL] [Abstract][Full Text] [Related]
11. Disruption of BSEP Function in HepaRG Cells Alters Bile Acid Disposition and Is a Susceptive Factor to Drug-Induced Cholestatic Injury. Qiu X; Zhang Y; Liu T; Shen H; Xiao Y; Bourner MJ; Pratt JR; Thompson DC; Marathe P; Humphreys WG; Lai Y Mol Pharm; 2016 Apr; 13(4):1206-16. PubMed ID: 26910619 [TBL] [Abstract][Full Text] [Related]
12. Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury. Petrescu AD; DeMorrow S Cells; 2021 Jul; 10(8):. PubMed ID: 34440614 [TBL] [Abstract][Full Text] [Related]
13. Critical Factors in the Assessment of Cholestatic Liver Injury In Vitro. Woolbright BL; Jaeschke H Methods Mol Biol; 2015; 1250():363-76. PubMed ID: 26272158 [TBL] [Abstract][Full Text] [Related]
14. Serotonin protects mouse liver from cholestatic injury by decreasing bile salt pool after bile duct ligation. Jang JH; Rickenbacher A; Humar B; Weber A; Raptis DA; Lehmann K; Stieger B; Moritz W; Soll C; Georgiev P; Fischer D; Laczko E; Graf R; Clavien PA Hepatology; 2012 Jul; 56(1):209-18. PubMed ID: 22290718 [TBL] [Abstract][Full Text] [Related]
15. Inappropriate ileal conservation of bile acids in cholestatic liver disease: homeostasis gone awry. Hofmann AF Gut; 2003 Sep; 52(9):1239-41. PubMed ID: 12912852 [No Abstract] [Full Text] [Related]
16. Pravastatin modulates liver bile acid and cholesterol homeostasis in rats with chronic cholestasis. Kolouchova G; Brcakova E; Hirsova P; Sispera L; Tomsik P; Cermanova J; Hyspler R; Slanarova M; Fuksa L; Lotkova H; Micuda S J Gastroenterol Hepatol; 2011 Oct; 26(10):1544-51. PubMed ID: 21501227 [TBL] [Abstract][Full Text] [Related]
17. Hepatocellular bile salt transport: lessons from cholestasis. Trauner M; Fickert P; Stauber RE Can J Gastroenterol; 2000 Nov; 14 Suppl D():99D-104D. PubMed ID: 11110621 [TBL] [Abstract][Full Text] [Related]
18. Rat precision-cut liver slices predict drug-induced cholestatic injury. Starokozhko V; Greupink R; van de Broek P; Soliman N; Ghimire S; de Graaf IAM; Groothuis GMM Arch Toxicol; 2017 Oct; 91(10):3403-3413. PubMed ID: 28391356 [TBL] [Abstract][Full Text] [Related]
19. The emerging role of AMP-activated protein kinase in cholestatic liver diseases. Li X; Liu R; Zhang L; Jiang Z Pharmacol Res; 2017 Nov; 125(Pt B):105-113. PubMed ID: 28889972 [TBL] [Abstract][Full Text] [Related]
20. Progressive and Preferential Cellular Accumulation of Hydrophobic Bile Acids Induced by Cholestatic Drugs Is Associated with Inhibition of Their Amidation and Sulfation. Sharanek A; Burban A; Humbert L; Guguen-Guillouzo C; Rainteau D; Guillouzo A Drug Metab Dispos; 2017 Dec; 45(12):1292-1303. PubMed ID: 28928138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]